A preliminary fluorodeoxyglucose positron emission tomography study in healthy adults reporting dream-enactment behavior.
OBJECTIVE
To test the hypothesis that healthy adults reporting dream-enactment behavior (DEB+) have reduced cerebral metabolic rate for glucose (CMRgl) in regions preferentially affected in patients with dementia with Lewy bodies (DLB).


METHODS
Automated brain-mapping algorithms were used to compare regional fluorodeoxyglucose (FDG) positron emission tomography (PET) measurements from previously evaluated DEB cases and controls.


METHODS
Tertiary-care academic medical centers.


METHODS
Seventeen cognitively normal patients with DEB+ and 17 control subjects (DEB-) who were individually matched for age (59 +/- 11 years), education level (16 +/- 4 years), sex (67% women), body mass index (26 +/- 4.8 kg/m2), first-degree relative with dementia (85%), and proportion of apolipoprotein E (APOE) e4 carriers (13 e4 carriers, 4 noncarriers).


METHODS
FDG-PET.


RESULTS
DEB was associated with significantly lower CMRgl in several brain regions known to be preferentially affected in both DLB and Alzheimer disease (parietal, temporal, and posterior cingulate cortexes) and in several other regions, including the anterior cingulate cortex (p < .001, uncorrected for multiple comparisons). The DEB-associated CMRgl reductions were significantly greater in the APOE e4 noncarriers than in the carriers.


CONCLUSIONS
These preliminary findings suggest that cognitively normal persons with DEB have reduced CMRgl in brain regions known to be metabolically affected by DLB, supporting further study of DEB as a possible risk factor for the development of DLB.
Caselli
Richard J
RJ
Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA. caselli.richard@mayo.edu
Chen
Kewei
K
Bandy
Dan
D
Smilovici
Oded
O
Boeve
Bradley F
BF
Osborne
David
D
Alexander
Gene E
GE
Parish
James M
JM
Krahn
Lois E
LE
Reiman
Eric M
EM
D000328:Adult; D000465:Algorithms; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D001931:Brain Mapping; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012890:Sleep / Q000502:physiology*; D011795:Surveys and Questionnaires
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose